UK markets closed

Adocia SA (0QAI.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
9.73-0.69 (-6.64%)
At close: 05:10PM GMT
Full screen
Previous close10.42
Open10.00
Bid0.00 x 0
Ask0.00 x 0
Day's range9.73 - 10.00
52-week range2.80 - 16.16
Volume207
Avg. volume4,392
Market cap679,029
Beta (5Y monthly)0.92
PE ratio (TTM)N/A
EPS (TTM)-3.22
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    ADOCIA Reports Fourth Quarter 2023 Financial Results and Provides a Business Update

    LYON, France, February 27, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today reports financial results for its fourth quarter of 2023 and provides a business update.

  • Business Wire

    Number of Shares and Voting Rights of ADOCIA as of January 31st, 2024

    LYON, France, February 13, 2024--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with innovative formul

  • Business Wire

    ADOCIA Announces its Financial Calendar for 2024

    LYON, France, January 25, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today its financial calendar for 2024.